High-dose chemotherapy with stem cell reinfusion and growth factor support for solid tumors

Stem Cells
E G de VriesN H Mulder

Abstract

With the help of stem cell reinfusion and hematopoietic growth factors, it is possible to get up to a ten-fold dose increase for certain chemotherapeutic drugs. A number of reasons may have made high-dose chemotherapy less dangerous and therefore more acceptable in a more upfront treatment setting. One of these is the addition of peripheral stem cell harvest obtained after mobilization with a hematopoietic growth factor alone or after chemotherapy followed by a hematopoietic growth factor, which seems to result in a faster recovery of neutrophils and platelets compared to bone marrow reinfusion alone. The combination of various hematopoietic growth factors could potentially improve hematopoietic recovery of the high-dose chemotherapy regimen. The relevance of tumor cells sometimes present in the reinfused hematopoietic stem cells is as yet unknown. High-dose chemotherapy may be interesting for a number of solid tumors such as nonseminomatous testicular carcinoma, breast carcinoma in the metastatic and adjuvant setting, ovarian carcinoma, tumors of young adults such as Ewing sarcoma and small cell lung carcinoma. In patients with refractory nonseminomatous testicular cancer there have been a number of studies performed with high...Continue Reading

References

Oct 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I J DielG Bastert
Oct 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J CoteM P Osborne
Dec 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K M TaylorL M Souza
Jan 1, 1988·British Journal of Cancer·D GlavesL Weiss
Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y H DattaM S Roth
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G SpitzerW McIntyre
Jan 1, 1994·International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement·L De LeijM J Mattes
Jan 1, 1994·International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement·W HelfrichL De Leij
Jan 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R PettengellN G Testa
Aug 1, 1993·Immunology Today·P HerrlichH Ponta
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J VeldhuisE G de Vries
Jan 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B CoiffierM L Symann
Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I TeplerM Muto
Jan 1, 1993·Stem Cells·S GulatiC Van-Poznak
Jun 1, 1992·Trends in Cell Biology·F Van Roy, M Mareel

❮ Previous
Next ❯

Citations

Jun 1, 1996·Medical Oncology·M HanssonP Engervall
Mar 1, 2012·PloS One·Stephanie L RellickLaura F Gibson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.